Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 2Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1HIV Infections 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Anus Neoplasms 1

Interventions

Doxorubicin 13Zidovudine 12Vincristine 11Bleomycin 8Cyclophosphamide 7Interferon alpha-2 6Etoposide 5Dexamethasone 5sargramostim 4Specimen Handling 4Methotrexate 4Magnetic Resonance Spectroscopy 4Leucovorin 4Filgrastim 4Cytarabine 4Rituximab 3Prednisone 3Nivolumab 3interferon alfa-n1 2cabozantinib 2Thalidomide 2Isotretinoin 2Interleukin-2 2Fluorouracil 2Didanosine 2Bortezomib 2Biopsy 2Allopurinol 2prednylidene 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × HIV Infections × Sentinel Lymph Node Biopsy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡